SCHEMBL6184491

SCHEMBL6184491

CNC(=O)OCc1cccc(-c2ccc(CC3SC(=O)NC3=O)cc2C)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 7/20 0.61
ALDH1A1 P00352 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
PPARG P37231 4/20 0.46
PPARA Q07869 1/20 0.46
MAOA P21397 2/20 0.45
CISD1 Q9NZ45 2/20 0.45
MAOB P27338 1/20 0.45
MPC2 O95563 1/20 0.41
CYP2C8 P10632 1/20 0.41
CYP2C9 P11712 1/20 0.41
PTPN1 P18031 2/20 0.40
FLT3 P36888 1/20 0.40
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
PTBP1 P26599 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182749 0.84 FFAR1 (0.59) FFAR1ALDH1A1NPSR1PPARGPPARA
SCHEMBL6183022 0.84 FFAR1 (0.52) FFAR1ALDH1A1NPSR1PPARGPPARA
SCHEMBL5399312 0.81 FFAR1 (0.55) FFAR1ALDH1A1NPSR1PPARGPPARA
SCHEMBL6184488 0.79 FFAR1 (0.55) FFAR1ALDH1A1NPSR1PPARGPPARA
SCHEMBL7522025 0.78 FFAR1 (0.62) FFAR1ALDH1A1NPSR1PPARGPPARA
SCHEMBL6187415 0.75 PTPN1 (0.48) MAOAMAOBPTPN1MEN1KMT2A
SCHEMBL6183689 0.73 FFAR1 (0.49) FFAR1ALDH1A1NPSR1PPARGPPARA
SCHEMBL6185514 0.73 FFAR1 (0.42) FFAR1PPARGPPARAMAOAMAOB
SCHEMBL6480624 0.71 FFAR1 (0.58) FFAR1ALDH1A1NPSR1PPARGPPARA
SCHEMBL6202350 0.71 FFAR1 (0.73) FFAR1ALDH1A1NPSR1PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
EP-1309575-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS Galderma Research & Development (FR) 2003-05-14 EP disclosed
WO-2002012210-A9 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2002-04-18 WO disclosed
WO-2002012210-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD FFAR1 6/4885ALDH1A1 378/4885NPSR1 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.